nsc 664704 has been researched along with Alloxan Diabetes in 1 studies
kenpaullone: inhibits CDK1/cyclin B; structure in first source
kenpaullone : An indolobenzazepine that is paullone in which the hydrogen at position 9 is replaced by a bromo substituent. It is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3beta (GSK3beta).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, ZC | 1 |
| Donnelly, L | 1 |
| Li, J | 1 |
| Krishnamurthy, M | 1 |
| Riopel, M | 1 |
| Wang, R | 1 |
1 other study available for nsc 664704 and Alloxan Diabetes
| Article | Year |
|---|---|
Inhibition of Gsk3β activity improves β-cell function in c-KitWv/+ male mice.
Topics: Animals; B-Lymphocytes; Benzazepines; beta Catenin; Cell Proliferation; Cyclin D1; Diabetes Mellitus | 2012 |